Oncternal Therapeutics Axes B-Cell Lymphoma Trial for CAR-T Therapy ONCT-808
Oncternal Therapeutics is discontinuing its phase 1/2 ONCT-808-101 trial for ONCT-808, a CAR-T therapy targeting ROR1 in r/r aggressive B-cell lymphoma, due to capital requirements. ONCT-808 showed antitumor activity and long-term CAR T-cell persistence, but one patient died from shock complications. The company is also halting trials for ONCT-534, zilovertamab, and ONCT-216, and reducing its workforce to explore strategic alternatives.
Related Clinical Trials
Reference News
Oncternal Therapeutics is discontinuing its phase 1/2 ONCT-808-101 trial for ONCT-808, a CAR-T therapy targeting ROR1 in r/r aggressive B-cell lymphoma, due to capital requirements. ONCT-808 showed antitumor activity and long-term CAR T-cell persistence, but one patient died from shock complications. The company is also halting trials for ONCT-534, zilovertamab, and ONCT-216, and reducing its workforce to explore strategic alternatives.